Press release
Hepatitis-B-Virus Infection Pipeline and Clinical Trials Pipeline Analysis 2023 (Updated): 80+ Companies are working to improve the Treatment of Space | Arbutus Biopharma, Vir Biotechnology, and others
Hepatitis B Virus (HBV) Infection Pipeline
In the Hepatitis-b-Virus Infection Pipeline Report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, Hepatitis-b-Virus Infection NDA approvals (if any), and product development activities comprising the technology, Hepatitis B Virus (HBV) Infection collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
To explore more information on the latest breakthroughs in the Hepatitis-b-Virus Infection Pipeline treatment landscape of the report, click here @ https://www.delveinsight.com/report-store/hepatitis-b-virus-hbv-infection-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key Takeaways from the Hepatitis-b-Virus Infection Pipeline Report
• DelveInsight's Hepatitis-b-Virus Infection Pipeline analysis depicts a robust space with 80+ active players working to develop 80+ pipeline treatment therapies.
• The leading Hepatitis-b-Virus Infection Companies are working in the market include Assembly Biosciences, Arbutus Biopharma, Vir Biotechnology, Nucorion Pharmaceuticals, Gilead Sciences, Dong-A ST Co., Ltd., Assembly Biosciences, Antios Therapeutics, Ascletis Pharmaceuticals, Shanghai HEP Pharmaceutical, Romark Laboratories, Qilu Pharmaceutical, Golden Biotechnology, Sunshine Lake Pharma, Ascentage Pharma, Vir Biotechnology, GlaxoSmithKline, Janssen Sciences, Henlix, Enyo Pharma, Tasly Tianjin Biopharmaceutical, Brii Biosciences, Vaxine Pty Ltd, Vaccitech limited, Zhejiang Palo Alto Pharmaceuticals, Suzhou Ribo Life Science, PharmaEssentia, Jiangsu HengRui Medicine, Enanta Pharmaceuticals, Chong Kun Dang Pharmaceutical, Guangzhou Lupeng Pharmaceutical, VenatoRx Pharmaceuticals, Zhimeng Biopharma, ISA Pharmaceuticals, Dicerna Pharmaceuticals, and others
• Promising Hepatitis-B-Virus Infection Pipeline Therapies in the various stages of development include EYP001a, HB-AS02V, HBVAXPRO vaccine, FENDRIX, Tenofovir Disoproxil Fumarate, NCO-48 Fumarate 4 mg, Telbivudine, valtorcitabine, Selgantolimod, lamivudine, APG-1387 for Injection, and others
• On June 2023, Gilead Sciences has announced drug named Tenofovir Alafenamide, VIR-2218, and Selgantolimod in the market by the phase 2. The primary objectives of this study are to evaluate the safety and tolerability of study treatment(s) (selgantolimod-containing combination therapies) and to evaluate the efficacy of study treatment(s) as measured by the proportion of participants who achieve functional cure, defined as hepatitis B surface antigen (HBsAg) loss and hepatitis B virus (HBV) deoxyribonucleic acid (DNA) < lower limit of quantitation (LLOQ) at Follow-up (FU) Week 24 in participants with chronic hepatitis B (CHB).
• On January 2023, Nucorion Pharmaceuticals Inc has announced NCO-48 Fumarate 4 mg, and Tenofovir Alafenamide 25 mg in the market by the phase 1. This is a randomized, open-label, active comparator, multiple oral dose study to evaluate the safety, tolerability, pharmacokinetics, and anti-hepatitis B virus (HBV) activity of NCO-48 Fumarate in treatment-naive adults with chronic HBV infection. This study will evaluate the safety, viral kinetics, and antiviral activity of 2 different doses of NCO-48 Fumarate over 28 days of therapy. In addition, the study will evaluate the antiviral activity of an optimal dose of NCO-48 Fumarate versus 25 mg tenofovir alafenamide (TAF) over 28 days of therapy.
Hepatitis-b-Virus Infection Overview
Hepatitis B virus is a small DNA virus that belongs to the "Hepadnaviridae" family. It is a vaccine-preventable liver infection caused by the HBV. A hepatitis B infection can result in either an acute infection or a chronic infection.
Chronic hepatitis B infection can be treated with medicines, including oral antiviral agents. The treatment can result in slowing the progression of cirrhosis, reduce incidence of liver cancer and improve long term survival. Peginterferon alfa 2-acan also be used in treatment as it stimulates the immune system to attack the HBV and regain control over it.
For further information, refer to the detailed Hepatitis-b-Virus Infection Unmet Needs, click here for Hepatitis-b-Virus Infection Ongoing Clinical Trial Analysis @ https://www.delveinsight.com/sample-request/hepatitis-b-virus-hbv-infection-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Hepatitis-b-Virus Infection Emerging Drugs Profile
• VIR 2218: Vir Biotechnology
• ABI H3733: Assembly Biosciences
• AB 729: Arbutus Biopharma
Hepatitis-B-Virus Infection Pipeline Therapeutics Assessment
There are approx. 80+ Hepatitis-b-Virus Infection companies which are developing the therapies for Hepatitis B Virus (HBV) Infection. The Hepatitis-b-Virus Infection companies which have their Hepatitis B Virus (HBV) Infection drug candidates in the most advanced stage, i.e. phase II include, Arbutus Biopharma.
Request a sample and discover the recent advances in Hepatitis-b-Virus Infection Ongoing Clinical Trial Analysis and Medications, click here @ https://www.delveinsight.com/sample-request/hepatitis-b-virus-hbv-infection-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Hepatitis-b-Virus Infection Drugs and Companies
• PBGENE-HBV: Precision Biosciences
• SBT8230: Silverback Therapeutics
• VIR-3434: Vir Biotechnology
• RG6346: Dicerna Pharmaceuticals
• RG7854: Roche
• Pradefovir: Ligand Pharmaceutical
• AB 729: Arbutus bio
Hepatitis-B-Virus Infection Market Drivers
• High prevalence of chronic HBV infection
• Rising case of liver cancer and cirrhosis deaths due to HBV infection
Hepatitis-B-Virus Infection Market Barriers
• Expensive Treatment
• Limited access to the diagnosis
Hepatitis B Virus Infection Therapeutics Assessment
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type
Some of the Companies in the Hepatitis B Virus Infection Therapeutics Market include-
Assembly Biosciences, Arbutus Biopharma, Vir Biotechnology, Nucorion Pharmaceuticals, Gilead Sciences, Dong-A ST Co., Ltd., Assembly Biosciences, Antios Therapeutics, Ascletis Pharmaceuticals, Shanghai HEP Pharmaceutical, Romark Laboratories, Qilu Pharmaceutical, Golden Biotechnology, Sunshine Lake Pharma, Ascentage Pharma, Vir Biotechnology, GlaxoSmithKline, Janssen Sciences, Henlix, Enyo Pharma, Tasly Tianjin Biopharmaceutical, Brii Biosciences, Vaxine Pty Ltd, Vaccitech limited, Zhejiang Palo Alto Pharmaceuticals, Suzhou Ribo Life Science, PharmaEssentia, Jiangsu HengRui Medicine, Enanta Pharmaceuticals, Chong Kun Dang Pharmaceutical, Guangzhou Lupeng Pharmaceutical, VenatoRx Pharmaceuticals, Zhimeng Biopharma, ISA Pharmaceuticals, Dicerna Pharmaceuticals, and others.
Dive deep into rich insights for drugs for Hepatitis-b-Virus Infection Pipeline, click here for Hepatitis-b-Virus Infection Unmet Needs and Analyst Views @ https://www.delveinsight.com/sample-request/hepatitis-b-virus-hbv-infection-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Scope of the Hepatitis-b-Virus Infection Pipeline Report
• Coverage- Global
• Hepatitis-b-Virus Infection Companies- Assembly Biosciences, Arbutus Biopharma, Vir Biotechnology, Nucorion Pharmaceuticals, Gilead Sciences, Dong-A ST Co., Ltd., Assembly Biosciences, Antios Therapeutics, Ascletis Pharmaceuticals, Shanghai HEP Pharmaceutical, Romark Laboratories, Qilu Pharmaceutical, Golden Biotechnology, Sunshine Lake Pharma, Ascentage Pharma, Vir Biotechnology, GlaxoSmithKline, Janssen Sciences, Henlix, Enyo Pharma, Tasly Tianjin Biopharmaceutical, Brii Biosciences, Vaxine Pty Ltd, Vaccitech limited, Zhejiang Palo Alto Pharmaceuticals, Suzhou Ribo Life Science, PharmaEssentia, Jiangsu HengRui Medicine, Enanta Pharmaceuticals, Chong Kun Dang Pharmaceutical, Guangzhou Lupeng Pharmaceutical, VenatoRx Pharmaceuticals, Zhimeng Biopharma, ISA Pharmaceuticals, Dicerna Pharmaceuticals, and others.
• Hepatitis-b-Virus Infection Therapies- EYP001a, HB-AS02V, HBVAXPRO vaccine, FENDRIX, Tenofovir Disoproxil Fumarate, NCO-48 Fumarate 4 mg, Telbivudine, valtorcitabine, Selgantolimod, lamivudine, APG-1387 for Injection, and others
• Hepatitis B Virus Infection Segmentation: Product Type, Molecule Type, Route of Administration
Got Queries? Find out the related information on Hepatitis-b-Virus Infection Merger and acquisitions, Licensing Activities @ https://www.delveinsight.com/sample-request/hepatitis-b-virus-hbv-infection-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Table of Content
1. Introduction
2. Executive Summary
3. Hepatitis B Virus (HBV) Infection: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Hepatitis B Virus (HBV) Infection- DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. Drug name : Company name
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. AB 729: Arbutus Biopharma
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. ABI H3733: Assembly Biosciences
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug name: Company name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Hepatitis B Virus (HBV) Infection Key Companies
21. Hepatitis B Virus (HBV) Infection Key Products
22. Hepatitis B Virus (HBV) Infection- Unmet Needs
23. Hepatitis B Virus (HBV) Infection- Market Drivers and Barriers
24. Hepatitis B Virus (HBV) Infection- Future Perspectives and Conclusion
25. Hepatitis B Virus (HBV) Infection Analyst Views
26. Hepatitis B Virus (HBV) Infection Key Companies
27. Appendix
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Hepatitis-B-Virus Infection Pipeline and Clinical Trials Pipeline Analysis 2023 (Updated): 80+ Companies are working to improve the Treatment of Space | Arbutus Biopharma, Vir Biotechnology, and others here
News-ID: 3145941 • Views: …
More Releases from DelveInsight Business Research
Spinocerebellar Ataxias Pipeline 2025: Comprehensive Clinical Trials and Therapi …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Spinocerebellar Ataxias pipeline constitutes 8+ key companies continuously working towards developing 10+ Spinocerebellar Ataxias treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Spinocerebellar Ataxias Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Spinocerebellar Ataxias Market.
The Spinocerebellar…
Presbyopia Market to Evolve Rapidly Over the Next Decade by 2034, DelveInsight O …
The Presbyopia market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Presbyopia pipeline products will significantly revolutionize the Presbyopia market dynamics.
DelveInsight's "Presbyopia Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Presbyopia, historical and forecasted epidemiology as well as the Presbyopia market trends in the United States, EU5 (Germany, Spain, Italy, France,…
Idiopathic Pulmonary Fibrosis Market Insights Highlight Expanding Outlook Till 2 …
DelveInsight's "Idiopathic Pulmonary Fibrosis Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Idiopathic Pulmonary Fibrosis, historical and forecasted epidemiology as well as the Idiopathic Pulmonary Fibrosis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
The latest healthcare forecast report provides an in-depth analysis of Idiopathic Pulmonary Fibrosis, offering comprehensive insights into the Idiopathic Pulmonary Fibrosis revenue trends,…
Myocardial Infarction Market Positioned for Accelerated Development Through 2034 …
DelveInsight's "Myocardial Infarction Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Myocardial Infarction, historical and forecasted epidemiology as well as the Myocardial Infarction market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Myocardial Infarction market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Myocardial Infarction Market Forecast
https://www.delveinsight.com/sample-request/myocardial-infarction-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the…
More Releases for Vir
Influenza A Market: Epidemiology, Therapies, Companies, DelveInsight | Cidara Th …
Influenza A therapies, such as XOFLUZA, RAPIVAB, FLUAD QUADRIVALENT, mRNA-1010, CD388, Flu Pandemic mRNA (GSK4382276A), CC-42344, and others, are expected to boost the Influenza A Market in the upcoming years.
DelveInsight has launched a new report on "Influenza A - Market Insights, Epidemiology, and Market Forecast-2034" that delivers an in-depth understanding of the Influenza A, historical and forecasted epidemiology as well as the Influenza A market trends in the United States,…
Investigation for NASDAQ: VIR Investors over possible Wrongdoing at Vir Biotechn …
An investigation was announced over potential breaches of fiduciary duties by certain directors at Vir Biotechnology, Inc.
Investors who purchased shares of Vir Biotechnology, Inc. (NASDAQ: VIR) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm concerns whether certain Vir Biotechnology directors breached their fiduciary duties and caused damage to the company and its shareholders.
San Francisco, CA based…
SOFTWARE-DEFINED NETWORKING AND NETWORK FUTUALIZATION MARKET knowNCTION VIR indu …
“The SDN and NFV is picking up noticeable quality because of the developing mechanical progressions in systems administration and server farm union. SDN is a momentous systems administration design, which is ready to totally alter the current systems administration and server farm foundation. The SDN building structure is set to reclassify the systems administration framework to meet the developing number of system clients devouring a high data transfer capacity. With…
Investigation announced for Investors in shares of Vir Biotechnology, Inc. (NASD …
Vir Biotechnology, Inc is under investigation concerning potential securities laws violations in connection with certain financial statements.
Investors who purchased shares of Vir Biotechnology, Inc. (NASDAQ: VIR), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm focuses on whether a series of statements by Vir Biotechnology, Inc. regarding its business, its prospects and its operations were materially false…
Global Balancing Valves Market 2017 - IMI Hydronic, Danfoss, Frese A/S, Caleffi, …
"A balancing valve is a measurement and regulation device. Balancing valves are used in pressurized piping applications, such as HVAC and gas movement applications. The main purpose of a balancing valve is generally to create a consistent output pressure to a system from an inconsistent input pressure from a different system."
Scope of the Report:
This report focuses on the Balancing Valves in Global market, especially in North America, Europe and Asia-Pacific,…
Automatic Balancing Valves Market Research Report 2017: IMI Hydronic, Danfoss, F …
In this report, the global Automatic Balancing Valves market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.
Request for sample of Automatic Balancing Valves Market research report @ https://www.qyresearchgroups.com/request-sample/365951
Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate…
